Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Endometrial Cancer | Research article

Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer

Authors: Rong Cong, Fanfei Kong, Jian Ma, Qing Li, Qijun Wu, Xiaoxin Ma

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The preoperative peripheral blood neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) have been reported to be associated with the prognosis of various cancers but are always discussed separately. The aim of this study is to bring the combination of NLR, PLR and MLR into the prognostic assessment system of endometrial cancer (EC) and establish a nomogram to provide an objective prediction model for clinical decisions.

Methods

A total of 1111 patients with EC who had accepted surgical treatment during 2013–2017 were involved in the analysis. Their NLR, PLR, and MLR levels were obtained from a routine blood examination within 2 weeks before operation. Receiver operating characteristic curve (ROC) analysis was performed to determine optimal cutoffs. Chi-square tests analysed the associations of the ratios with other clinicopathological variables. The prognostic value was indicated by overall survival (OS) via Cox proportional hazards models and Kaplan-Meier analysis. R software was used to establish the nomogram based on the combination of NLR, PLR, MLR and other clinicopathological factors.

Results

The median follow-up period was 40 months, and the median age was 56. The enrolled patients were stratified by cutoffs of 2.14 for NLR, 131.82 for PLR and 0.22 for MLR. Multivariate analyses demonstrated that high NLR over 2.14 (HR = 2.71, 95%CI = 1.83–4.02, P<0.001), high PLR over 131.82 (HR = 2.75, 95%CI = 1.90–3.97, P<0.001), and high MLR over 0.22 (HR = 1.72, 95%CI = 1.20–2.45, P = 0.003) were significantly associated with worse OS. The combined indicator, high NLR + high PLR + high MLR (HR = 4.34, 95%CI = 2.54–7.42, P<0.001), showed the highest prognostic value. The Harrell’s concordance index of the nomogram was 0.847 (95% CI = 0.804–0.890), showing good discrimination and calibration of this model.

Conclusion

The combination of NLR, PLR, and MLR is a superior prognostic factor of EC. The nomogram involving the combination of NLR, PLR, MLR and other clinicopathological factors is recommended to predict OS for EC patients clinically.
Appendix
Available only for authorised users
Literature
1.
go back to reference Temur I, Kucukgoz GU, Paydas S, Guzel AB, Sucu M, Vardar MA. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2018;226:25–9.CrossRef Temur I, Kucukgoz GU, Paydas S, Guzel AB, Sucu M, Vardar MA. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2018;226:25–9.CrossRef
2.
go back to reference Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094–108.CrossRef Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094–108.CrossRef
3.
go back to reference Rizner TL. Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn. 2016;6:1315–36.CrossRef Rizner TL. Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn. 2016;6:1315–36.CrossRef
4.
go back to reference Kim BW, Jeon YE, Cho H, Nam EJ, Kim SW, Kim S, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. J Obstet Gynaecol Res. 2012;38:48–56.CrossRef Kim BW, Jeon YE, Cho H, Nam EJ, Kim SW, Kim S, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. J Obstet Gynaecol Res. 2012;38:48–56.CrossRef
5.
go back to reference Ding L, Ding Y, Mao XH, Zhao JF, Zhou HJ. Retrospective study of the prognostic significance of neutrophil-to-lymphocyte ratio for postsurgical outcomes of patients with endometrial carcinoma. Int J Gynaecol Obstet. 2017;138:311–9.CrossRef Ding L, Ding Y, Mao XH, Zhao JF, Zhou HJ. Retrospective study of the prognostic significance of neutrophil-to-lymphocyte ratio for postsurgical outcomes of patients with endometrial carcinoma. Int J Gynaecol Obstet. 2017;138:311–9.CrossRef
6.
go back to reference Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, et al. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci. 2017;108:193–9.CrossRef Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, et al. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci. 2017;108:193–9.CrossRef
7.
go back to reference Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8:4135–48.PubMedPubMedCentral Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8:4135–48.PubMedPubMedCentral
8.
go back to reference Li X, Zeng WH, Zhou YQ, Ji YY, Li WZ, Zhang LY, et al. Neutrophil-to-lymphocyte ratio predicted long-term chemotherapy benefits in stage IIIB-IV non-squamous non-small cell lung Cancer patients without sensitive mutations. Onco Targets Ther. 2019;12:8779–87.CrossRef Li X, Zeng WH, Zhou YQ, Ji YY, Li WZ, Zhang LY, et al. Neutrophil-to-lymphocyte ratio predicted long-term chemotherapy benefits in stage IIIB-IV non-squamous non-small cell lung Cancer patients without sensitive mutations. Onco Targets Ther. 2019;12:8779–87.CrossRef
9.
go back to reference Dimitriou N, Felekouras E, Karavokyros I, Alexandrou A, Pikoulis E, Griniatsos J. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer. 2018;18:1202.CrossRef Dimitriou N, Felekouras E, Karavokyros I, Alexandrou A, Pikoulis E, Griniatsos J. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer. 2018;18:1202.CrossRef
10.
go back to reference Mori M, Shuto K, Kosugi C, Narushima K, Hayashi H, Matsubara H, et al. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer. 2018;18:1261.CrossRef Mori M, Shuto K, Kosugi C, Narushima K, Hayashi H, Matsubara H, et al. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer. 2018;18:1261.CrossRef
11.
go back to reference Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, et al. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study. Gynecol Oncol. 2015;137:112–8.CrossRef Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, et al. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study. Gynecol Oncol. 2015;137:112–8.CrossRef
12.
go back to reference Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T, et al. Pretreatment neutrophil-to-lymphocyte ratio was a predictor of lymph node metastasis in endometrial Cancer patients. Oncology. 2019:1–9. Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T, et al. Pretreatment neutrophil-to-lymphocyte ratio was a predictor of lymph node metastasis in endometrial Cancer patients. Oncology. 2019:1–9.
13.
go back to reference Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther. 2017;45:1413–26.CrossRef Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther. 2017;45:1413–26.CrossRef
14.
go back to reference Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in Intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:339–45.CrossRef Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in Intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:339–45.CrossRef
15.
go back to reference Eo WK, Kwon S, Koh SB, Kim MJ, Ji YI, Lee JY, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial Cancer. J Cancer. 2016;7:538–45.CrossRef Eo WK, Kwon S, Koh SB, Kim MJ, Ji YI, Lee JY, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial Cancer. J Cancer. 2016;7:538–45.CrossRef
16.
go back to reference Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 2018;18:1280.CrossRef Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 2018;18:1280.CrossRef
17.
go back to reference Liang Y, Wang W, Li J, Guan Y, Que Y, Xiao W, et al. Combined use of the neutrophil-lymphocyte and platelet-lymphocyte ratios as a prognostic predictor in patients with operable soft tissue sarcoma. J Cancer. 2018;9:2132–9.CrossRef Liang Y, Wang W, Li J, Guan Y, Que Y, Xiao W, et al. Combined use of the neutrophil-lymphocyte and platelet-lymphocyte ratios as a prognostic predictor in patients with operable soft tissue sarcoma. J Cancer. 2018;9:2132–9.CrossRef
18.
go back to reference Huang Z, Liu Y, Yang C, Li X, Pan C, Rao J, et al. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. BMC Cancer. 2018;18:515.CrossRef Huang Z, Liu Y, Yang C, Li X, Pan C, Rao J, et al. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. BMC Cancer. 2018;18:515.CrossRef
19.
go back to reference Yen MS, Chen TH, Ke YM, Hsu KF, Chen JR, Yu MH, et al. Clinicopathologic Features and Treatment Outcomes in Patients with Stage I, High-Risk Histology or High-Grade Endometrial Cancer after Primary Staging Surgery: A Taiwanese Gynecologic Oncology Group Study. J Clin Med. 2018;7:9.CrossRef Yen MS, Chen TH, Ke YM, Hsu KF, Chen JR, Yu MH, et al. Clinicopathologic Features and Treatment Outcomes in Patients with Stage I, High-Risk Histology or High-Grade Endometrial Cancer after Primary Staging Surgery: A Taiwanese Gynecologic Oncology Group Study. J Clin Med. 2018;7:9.CrossRef
20.
go back to reference Bendifallah S, Canlorbe G, Raimond E, Hudry D, Coutant C, Graesslin O, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014;110:2640–6.CrossRef Bendifallah S, Canlorbe G, Raimond E, Hudry D, Coutant C, Graesslin O, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014;110:2640–6.CrossRef
21.
go back to reference Mauland KK, Trovik J, Wik E, Raeder MB, Njolstad TS, Stefansson IM, et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011;104:921–6.CrossRef Mauland KK, Trovik J, Wik E, Raeder MB, Njolstad TS, Stefansson IM, et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011;104:921–6.CrossRef
22.
go back to reference Binder PS, Peipert JF, Kallogjeri D, Brooks RA, Massad LS, Mutch DG, et al. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. Am J Obstet Gynecol. 2016;215:766.e1 766.e9.CrossRef Binder PS, Peipert JF, Kallogjeri D, Brooks RA, Massad LS, Mutch DG, et al. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. Am J Obstet Gynecol. 2016;215:766.e1 766.e9.CrossRef
23.
go back to reference Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014;120:2986–95.CrossRef Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014;120:2986–95.CrossRef
24.
go back to reference Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–80.CrossRef Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–80.CrossRef
25.
go back to reference Ouldamer L, Bendifallah S, Body G, Touboul C, Graesslin O, Raimond E, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer. 2016;115:1296–303.CrossRef Ouldamer L, Bendifallah S, Body G, Touboul C, Graesslin O, Raimond E, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer. 2016;115:1296–303.CrossRef
26.
go back to reference Wang Y, Sun K, Shen J, Li B, Kuang M, Cao Q, et al. Novel prognostic Nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy. Cancer Res Treat. 2019;51:1464.CrossRef Wang Y, Sun K, Shen J, Li B, Kuang M, Cao Q, et al. Novel prognostic Nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy. Cancer Res Treat. 2019;51:1464.CrossRef
27.
go back to reference Choi JH, Suh YS, Choi Y, Han J, Kim TH, Park SH, et al. Comprehensive analysis of the neutrophil-to-lymphocyte ratio for preoperative prognostic prediction Nomogram in gastric Cancer. World J Surg. 2018;42:2530–41.CrossRef Choi JH, Suh YS, Choi Y, Han J, Kim TH, Park SH, et al. Comprehensive analysis of the neutrophil-to-lymphocyte ratio for preoperative prognostic prediction Nomogram in gastric Cancer. World J Surg. 2018;42:2530–41.CrossRef
28.
go back to reference Wang X, Mao M, He Z, Zhang L, Li H, Lin J, He Y, Dai S, Hu W, Liu W. Development and validation of a prognostic Nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–8.CrossRef Wang X, Mao M, He Z, Zhang L, Li H, Lin J, He Y, Dai S, Hu W, Liu W. Development and validation of a prognostic Nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–8.CrossRef
29.
go back to reference Abu-Shawer O, Abu-Shawer M, Hirmas N, Alhouri A, Massad A, Alsibai B, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19:141.CrossRef Abu-Shawer O, Abu-Shawer M, Hirmas N, Alhouri A, Massad A, Alsibai B, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19:141.CrossRef
30.
go back to reference Blaisdell A, Crequer A, Columbus D, Daikoku T, Mittal K, Dey SK, et al. Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell. 2015;28:785–99.CrossRef Blaisdell A, Crequer A, Columbus D, Daikoku T, Mittal K, Dey SK, et al. Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell. 2015;28:785–99.CrossRef
31.
go back to reference Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148:222–32.CrossRef Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148:222–32.CrossRef
32.
go back to reference D'Andrea D, Moschini M, Gust KM, Abufaraj M, Ozsoy M, Mathieu R, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017;115:455–61.CrossRef D'Andrea D, Moschini M, Gust KM, Abufaraj M, Ozsoy M, Mathieu R, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017;115:455–61.CrossRef
33.
go back to reference Asaka S, Yen T, Wang T, Shih I, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2018;32(4):576.CrossRef Asaka S, Yen T, Wang T, Shih I, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2018;32(4):576.CrossRef
Metadata
Title
Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer
Authors
Rong Cong
Fanfei Kong
Jian Ma
Qing Li
Qijun Wu
Xiaoxin Ma
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06953-8

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine